Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Neuropharmacology. 2013 Apr 12;71:191–203. doi: 10.1016/j.neuropharm.2013.03.038

Fig. 5.

Fig. 5

Reduction in L-dopa-induced AIMs with TI-10165. The treatment regimen with TI-10165 is depicted in the upper panel. All rats were unilaterally lesioned with 6-OHDA, pretreated with TI-10165 (0.1 mg/kg/d) for 2 wk via minipump and subsequently injected with L-dopa plus benserazide (8.0 mg/kg plus 15 mg/kg sc). After several wk at 0.1 mg/kg/d TI-10165, the initial minipump was replaced with one releasing 0.3 mg/kg/d. The rats were assessed for axial, oral and forelimb AIMs as indicated in the timeline, with the total AIMs representing the sum of these three components. The daily time course of the total L-dopa-induced AIMs is depicted in the graphs at the right. Values are the mean ± S.E.M. of 9–10 rats per group. Significance of difference from vehicle: *p < 0.05.